Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Direct Inhibitors
1.2.3 Signal transduction inhibitors
1.3 Market by Application
1.3.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Retail Pharmacy
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Perspective (2018-2029)
2.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Growth Trends by Region
2.2.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Historic Market Size by Region (2018-2024)
2.2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Region (2024-2029)
2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Dynamics
2.3.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industry Trends
2.3.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Drivers
2.3.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Challenges
2.3.4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players by Revenue
3.1.1 Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players by Revenue (2018-2024)
3.1.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Players (2018-2024)
3.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue
3.4 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Concentration Ratio
3.4.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in 2022
3.5 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Key Players Head office and Area Served
3.6 Key Players Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Solution and Service
3.7 Date of Enter into Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Breakdown Data by Type
4.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Historic Market Size by Type (2018-2024)
4.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Type (2024-2029)
5 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Breakdown Data by Application
5.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Historic Market Size by Application (2018-2024)
5.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
6.2 North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2018-2024)
6.4 North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
7.2 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2018-2024)
7.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
8.2 Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2018-2024)
8.4 Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
9.2 Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2018-2024)
9.4 Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
10.2 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2018-2024)
10.4 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.1.4 Amgen Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.1.5 Amgen Recent Development
11.2 Mirati Therapeutics
11.2.1 Mirati Therapeutics Company Detail
11.2.2 Mirati Therapeutics Business Overview
11.2.3 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.2.4 Mirati Therapeutics Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.2.5 Mirati Therapeutics Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.3.4 Novartis Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.3.5 Novartis Recent Development
11.4 Genentech
11.4.1 Genentech Company Detail
11.4.2 Genentech Business Overview
11.4.3 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.4.4 Genentech Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.4.5 Genentech Recent Development
11.5 Verastem Oncology
11.5.1 Verastem Oncology Company Detail
11.5.2 Verastem Oncology Business Overview
11.5.3 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.5.4 Verastem Oncology Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.5.5 Verastem Oncology Recent Development
11.6 Revolution Medicines
11.6.1 Revolution Medicines Company Detail
11.6.2 Revolution Medicines Business Overview
11.6.3 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.6.4 Revolution Medicines Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.6.5 Revolution Medicines Recent Development
11.7 Cardiff Oncology
11.7.1 Cardiff Oncology Company Detail
11.7.2 Cardiff Oncology Business Overview
11.7.3 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.7.4 Cardiff Oncology Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.7.5 Cardiff Oncology Recent Development
11.8 Immuneering Corporation
11.8.1 Immuneering Corporation Company Detail
11.8.2 Immuneering Corporation Business Overview
11.8.3 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.8.4 Immuneering Corporation Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.8.5 Immuneering Corporation Recent Development
11.9 Jacobio Pharmaceuticals
11.9.1 Jacobio Pharmaceuticals Company Detail
11.9.2 Jacobio Pharmaceuticals Business Overview
11.9.3 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.9.4 Jacobio Pharmaceuticals Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.9.5 Jacobio Pharmaceuticals Recent Development
11.10 BridgeBio Pharma
11.10.1 BridgeBio Pharma Company Detail
11.10.2 BridgeBio Pharma Business Overview
11.10.3 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.10.4 BridgeBio Pharma Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.10.5 BridgeBio Pharma Recent Development
11.11 Deciphera Pharmaceuticals
11.11.1 Deciphera Pharmaceuticals Company Detail
11.11.2 Deciphera Pharmaceuticals Business Overview
11.11.3 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.11.4 Deciphera Pharmaceuticals Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.11.5 Deciphera Pharmaceuticals Recent Development
11.12 Elicio Therapeutics
11.12.1 Elicio Therapeutics Company Detail
11.12.2 Elicio Therapeutics Business Overview
11.12.3 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.12.4 Elicio Therapeutics Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.12.5 Elicio Therapeutics Recent Development
11.13 InventisBio
11.13.1 InventisBio Company Detail
11.13.2 InventisBio Business Overview
11.13.3 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.13.4 InventisBio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.13.5 InventisBio Recent Development
11.14 Gritstone Bio
11.14.1 Gritstone Bio Company Detail
11.14.2 Gritstone Bio Business Overview
11.14.3 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.14.4 Gritstone Bio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.14.5 Gritstone Bio Recent Development
11.15 D3 Bio
11.15.1 D3 Bio Company Detail
11.15.2 D3 Bio Business Overview
11.15.3 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.15.4 D3 Bio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
11.15.5 D3 Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Direct Inhibitors
Table 3. Key Players of Signal transduction inhibitors
Table 4. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Region (2018-2024)
Table 8. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Region (2024-2029)
Table 10. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Trends
Table 11. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Drivers
Table 12. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Challenges
Table 13. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Restraints
Table 14. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Players (2018-2024)
Table 16. Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors as of 2022)
Table 17. Ranking of Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (CR5 and HHI) & (2018-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Solution and Service
Table 21. Date of Enter into Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Type (2018-2024)
Table 25. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Type (2024-2029)
Table 27. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Application (2018-2024)
Table 29. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Application (2024-2029)
Table 31. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2018-2024) & (US$ Million)
Table 33. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2018-2024) & (US$ Million)
Table 36. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2018-2024) & (US$ Million)
Table 39. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2018-2024) & (US$ Million)
Table 42. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2018-2024) & (US$ Million)
Table 45. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2024-2029) & (US$ Million)
Table 46. Amgen Company Detail
Table 47. Amgen Business Overview
Table 48. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 49. Amgen Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 50. Amgen Recent Development
Table 51. Mirati Therapeutics Company Detail
Table 52. Mirati Therapeutics Business Overview
Table 53. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 54. Mirati Therapeutics Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 55. Mirati Therapeutics Recent Development
Table 56. Novartis Company Detail
Table 57. Novartis Business Overview
Table 58. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 59. Novartis Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. Genentech Company Detail
Table 62. Genentech Business Overview
Table 63. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 64. Genentech Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 65. Genentech Recent Development
Table 66. Verastem Oncology Company Detail
Table 67. Verastem Oncology Business Overview
Table 68. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 69. Verastem Oncology Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 70. Verastem Oncology Recent Development
Table 71. Revolution Medicines Company Detail
Table 72. Revolution Medicines Business Overview
Table 73. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 74. Revolution Medicines Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 75. Revolution Medicines Recent Development
Table 76. Cardiff Oncology Company Detail
Table 77. Cardiff Oncology Business Overview
Table 78. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 79. Cardiff Oncology Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 80. Cardiff Oncology Recent Development
Table 81. Immuneering Corporation Company Detail
Table 82. Immuneering Corporation Business Overview
Table 83. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 84. Immuneering Corporation Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 85. Immuneering Corporation Recent Development
Table 86. Jacobio Pharmaceuticals Company Detail
Table 87. Jacobio Pharmaceuticals Business Overview
Table 88. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 89. Jacobio Pharmaceuticals Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 90. Jacobio Pharmaceuticals Recent Development
Table 91. BridgeBio Pharma Company Detail
Table 92. BridgeBio Pharma Business Overview
Table 93. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 94. BridgeBio Pharma Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 95. BridgeBio Pharma Recent Development
Table 96. Deciphera Pharmaceuticals Company Detail
Table 97. Deciphera Pharmaceuticals Business Overview
Table 98. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 99. Deciphera Pharmaceuticals Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 100. Deciphera Pharmaceuticals Recent Development
Table 101. Elicio Therapeutics Company Detail
Table 102. Elicio Therapeutics Business Overview
Table 103. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 104. Elicio Therapeutics Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 105. Elicio Therapeutics Recent Development
Table 106. InventisBio Company Detail
Table 107. InventisBio Business Overview
Table 108. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 109. InventisBio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 110. InventisBio Recent Development
Table 111. Gritstone Bio Company Detail
Table 112. Gritstone Bio Business Overview
Table 113. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 114. Gritstone Bio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 115. Gritstone Bio Recent Development
Table 116. D3 Bio Company Detail
Table 117. D3 Bio Business Overview
Table 118. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
Table 119. D3 Bio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024) & (US$ Million)
Table 120. D3 Bio Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Type: 2022 VS 2029
Figure 3. Direct Inhibitors Features
Figure 4. Signal transduction inhibitors Features
Figure 5. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 6. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Application: 2022 VS 2029
Figure 7. Retail Pharmacy Case Studies
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Online Pharmacy Case Studies
Figure 10. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Report Years Considered
Figure 11. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Region: 2022 VS 2029
Figure 14. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Players in 2022
Figure 15. Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in 2022
Figure 17. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Country (2018-2029)
Figure 19. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Country (2018-2029)
Figure 23. Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Region (2018-2029)
Figure 31. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Country (2018-2029)
Figure 39. Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Country (2018-2029)
Figure 43. Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Amgen Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 46. Mirati Therapeutics Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 47. Novartis Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 48. Genentech Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 49. Verastem Oncology Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 50. Revolution Medicines Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 51. Cardiff Oncology Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 52. Immuneering Corporation Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 53. Jacobio Pharmaceuticals Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 54. BridgeBio Pharma Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 55. Deciphera Pharmaceuticals Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 56. Elicio Therapeutics Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 57. InventisBio Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 58. Gritstone Bio Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 59. D3 Bio Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2018-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed